Saxenda 3ml Liraglutide Injection Pen

Clinical Breakthrough in Obesity Management

Saxenda (liraglutide 6mg/ml) is an FDA-approved GLP-1 receptor agonist for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions. Clinical trials demonstrate 56% of patients achieved ≥5% weight loss at 56 weeks when combined with lifestyle modifications, with an average 8% total body weight reduction. This 3ml pre-filled pen delivers 18mg of liraglutide through multidose subcutaneous injections.

GLP-1 receptor agonist with 97% amino acid sequence homology with human GLP-1. Reduces hunger through hypothalamic appetite center modulation and slows gastric emptying rate by 20-30%. Enhances first-phase insulin response by up to 118% through glucose-dependent insulin secretion.

Storage Information

Administration Guidelines